{"id":"bacillus-calmette-guerin-vaccine-intravesical","safety":{"commonSideEffects":[{"rate":"40-60","effect":"Dysuria"},{"rate":"40-60","effect":"Urinary frequency"},{"rate":"20-40","effect":"Hematuria"},{"rate":"10-20","effect":"Fever"},{"rate":"10-20","effect":"Malaise"},{"rate":"<1","effect":"BCG sepsis (rare)"}]},"_chembl":{"chemblId":"CHEMBL2108905","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"BCG (Bacillus Calmette-Guerin) is a live attenuated mycobacterium that triggers a potent local immune response in the bladder urothelium. When instilled intravesically, it activates dendritic cells, macrophages, and T cells to target and eliminate bladder cancer cells, particularly non-muscle-invasive urothelial carcinoma. This immunotherapy approach reduces recurrence and progression of bladder cancer.","oneSentence":"BCG vaccine stimulates the immune system to recognize and destroy bladder cancer cells when instilled directly into the bladder.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:43:06.456Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-muscle-invasive bladder cancer (NMIBC), high-grade urothelial carcinoma"},{"name":"Bladder cancer recurrence prevention"}]},"trialDetails":[{"nctId":"NCT03091660","phase":"PHASE3","title":"S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2017-02-24","conditions":"Stage 0 Bladder Urothelial Carcinoma, Stage 0is Bladder Urothelial Carcinoma, Stage I Bladder Urothelial Carcinoma","enrollment":1000},{"nctId":"NCT02138734","phase":"PHASE1, PHASE2","title":"A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer","status":"RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2014-07-21","conditions":"Non-muscle Invasive Bladder Cancer","enrollment":596},{"nctId":"NCT05714202","phase":"PHASE3","title":"A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2023-03-23","conditions":"Bladder Cancer","enrollment":1135},{"nctId":"NCT07474519","phase":"PHASE4","title":"Studying the Relationship of Patient Positioning and Intravesical Bacillus Calmette Guerin Dwell Time to Improve the Treatment of Non-muscle Invasive Bladder Cancer","status":"RECRUITING","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2026-02-26","conditions":"Non-Muscle Invasive Bladder Carcinoma","enrollment":40},{"nctId":"NCT05316155","phase":"PHASE1, PHASE2","title":"Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-04-11","conditions":"Non-Muscle Invasive Bladder Neoplasms","enrollment":235},{"nctId":"NCT07468851","phase":"PHASE1, PHASE2","title":"A Study of HS-10566 in Patients With High-risk Non-muscle-invasive Bladder Cancer Who Are Ineligible for or Refuse Radical Cystectomy","status":"NOT_YET_RECRUITING","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2026-06-10","conditions":"High-risk Non-muscle-invasive Bladder Cancer","enrollment":180},{"nctId":"NCT05943106","phase":"PHASE3","title":"BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-08-11","conditions":"Non-Muscle- Invasive Bladder Cancer","enrollment":100},{"nctId":"NCT07000084","phase":"PHASE3","title":"Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy","status":"RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2025-07-17","conditions":"Recurrent Non-Muscle Invasive Bladder Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8","enrollment":330},{"nctId":"NCT06545955","phase":"PHASE3","title":"A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer","status":"RECRUITING","sponsor":"Ferring Pharmaceuticals","startDate":"2024-10-01","conditions":"Non-muscle Invasive Bladder Cancer With Carcinoma in Situ","enrollment":250},{"nctId":"NCT05538663","phase":"PHASE3","title":"Intravesical BCG vs GEMDOCE in NMIBC","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2023-02-07","conditions":"Non-muscle-invasive Bladder Cancer","enrollment":870},{"nctId":"NCT04172675","phase":"PHASE2","title":"A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2020-02-28","conditions":"Urinary Bladder Neoplasms","enrollment":107},{"nctId":"NCT07424287","phase":"PHASE3","title":"A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC","status":"NOT_YET_RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2026-03","conditions":"NMIBC","enrollment":236},{"nctId":"NCT04752722","phase":"PHASE1, PHASE2","title":"LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve","status":"RECRUITING","sponsor":"enGene, Inc.","startDate":"2021-04-22","conditions":"Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ","enrollment":350},{"nctId":"NCT03711032","phase":"PHASE3","title":"Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-12-24","conditions":"High-risk Non-muscle Invasive Bladder Cancer","enrollment":1397},{"nctId":"NCT07268339","phase":"PHASE3","title":"A Phase III Randomised Control Clinical Trial of Radiotherapy With Radiosensitisation Versus Intravesical Bacillus Calmette-Guerin Therapy for High-risk Non-muscle Invasive Bladder Cancer.","status":"NOT_YET_RECRUITING","sponsor":"The Christie NHS Foundation Trust","startDate":"2025-12-01","conditions":"High-Risk Non-Muscle Invasive Bladder Cancer","enrollment":328},{"nctId":"NCT05768347","phase":"PHASE1","title":"Intravesical Adoptive Cell Therapy w/ TIL for BCG Exposed High Grade NMIBC","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2023-08-10","conditions":"Urothelial Carcinoma, Non-Invasive Bladder Urothelial Carcinoma","enrollment":9},{"nctId":"NCT05672615","phase":"","title":"Mood Alterations in the Patients With Non-Muscle Invasive Bladder Cancer Treated With BCG","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2023-03-21","conditions":"Non-Muscle Invasive Bladder Cancer","enrollment":42},{"nctId":"NCT03933826","phase":"","title":"CISTO: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Washington","startDate":"2019-07-09","conditions":"Bladder Cancer, Cancer of the Bladder, Recurrent, Non-muscle Invasive Bladder Cancer","enrollment":570},{"nctId":"NCT03022825","phase":"PHASE2, PHASE3","title":"QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2017-06-02","conditions":"Bladder Cancer","enrollment":190},{"nctId":"NCT06704191","phase":"PHASE1, PHASE2","title":"In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-04-21","conditions":"Non-Muscle Invasive Bladder Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8","enrollment":40},{"nctId":"NCT04149574","phase":"PHASE3","title":"A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC)","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2020-01-15","conditions":"Urinary Bladder Neoplasms","enrollment":13},{"nctId":"NCT07064863","phase":"PHASE1, PHASE2","title":"A Tumor Immune Biomarker Guided Approach for Improving Response to BCG in Patients With High-risk NMIBC.","status":"NOT_YET_RECRUITING","sponsor":"Queen's University","startDate":"2025-08-01","conditions":"NMIBC, Non-Muscle Invasive Bladder Urothelial Carcinoma, Bladder (Urothelial, Transitional Cell) Cancer","enrollment":31},{"nctId":"NCT02015104","phase":"PHASE2","title":"Study of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCG","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2013-12-18","conditions":"Bladder Cancer","enrollment":32},{"nctId":"NCT06816017","phase":"PHASE1","title":"A Study to Evaluate Eciskafusp Alfa in Combination With Bacillus Calmette-guerin (BCG) in Participants With BCG-unresponsive High-risk Non-muscle Invasive Bladder Cancer (NMIBC)","status":"WITHDRAWN","sponsor":"Hoffmann-La Roche","startDate":"2025-06-15","conditions":"Non-muscle Invasive Bladder Cancer","enrollment":""},{"nctId":"NCT05981131","phase":"","title":"Follow up of Intravesical N-803 Plus BCG in BCG-Naive Non-Muscle Invasive Bladder Cancer (NMIBC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2023-08-17","conditions":"Non Muscle Invasive Bladder Cancer","enrollment":6},{"nctId":"NCT02202772","phase":"PHASE1, PHASE2","title":"Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment Urothelial Carcinoma of the Bladder","status":"ACTIVE_NOT_RECRUITING","sponsor":"Guarionex J. Decastro","startDate":"2014-12-01","conditions":"Urothelial Carcinoma of the Urinary Bladder","enrollment":51},{"nctId":"NCT01697306","phase":"PHASE2","title":"The Impact of Intravesical Gemcitabine and 1/3 Dose Bacillus Calmette-Guerin on the Quality of Life in Superficial Bladder Cancer","status":"COMPLETED","sponsor":"A.O.U. Città della Salute e della Scienza","startDate":"2006-09","conditions":"Bladder Cancer","enrollment":120},{"nctId":"NCT03799835","phase":"PHASE3","title":"Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2019-01-17","conditions":"Bladder Cancer","enrollment":517},{"nctId":"NCT04142359","phase":"","title":"PK Sub-Study of QUILT-3.032 (CA ALT-803-01-16) and of QUILT-2.005 (CA ALT-803-01-14)","status":"TERMINATED","sponsor":"Altor BioScience","startDate":"2019-12-09","conditions":"Pharmacokinetics","enrollment":1},{"nctId":"NCT02773849","phase":"PHASE3","title":"ADSTILADRIN (=INSTILADRIN) in Patients With High-Grade, Bacillus Calmette-Guerin (BCG) Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2016-09-19","conditions":"Superficial Bladder Cancer","enrollment":157},{"nctId":"NCT06187506","phase":"PHASE2","title":"Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-12-18","conditions":"Non-muscle Invasive Bladder Cancer, HER-2 Protein Overexpression","enrollment":20},{"nctId":"NCT02808143","phase":"PHASE1","title":"Pembrolizumab and BCG Solution in Treating Patients With Recurrent Non-Muscle-Invasive Bladder Cancer","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2017-02-10","conditions":"Recurrent Bladder Carcinoma, Stage 0a Bladder Urothelial Carcinoma, Stage 0is Bladder Urothelial Carcinoma","enrollment":9},{"nctId":"NCT06462001","phase":"PHASE3","title":"BCG + MMC: Adding Mitomycin C to BCG in High-risk, Non-muscle-invasive Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nottingham University Hospitals NHS Trust","startDate":"2020-12-10","conditions":"Transitional Cell Carcinoma, Transurethral Resection","enrollment":500},{"nctId":"NCT06350838","phase":"PHASE1","title":"Clinical Study to Investigate the Safety and Tolerance of Therapeutic BCG in Postoperative Adjuvant Therapy in Subjects With Moderate to High-risk Non-muscular Invasive Bladder Cancer (NMIBC)","status":"COMPLETED","sponsor":"Chengdu CoenBiotech Co., Ltd","startDate":"2022-11-11","conditions":"Non-muscular Invasive Bladder Cancer","enrollment":10},{"nctId":"NCT06324058","phase":"NA","title":"Cryoablation Versus BCG Instillation Therapy for High-risk NMIBC","status":"NOT_YET_RECRUITING","sponsor":"Huashan Hospital","startDate":"2024-03-18","conditions":"Bladder Cancer","enrollment":190},{"nctId":"NCT06255964","phase":"PHASE1, PHASE2","title":"A Study of IAP0971 in Combination With Bacillus Calmette Guerin in High Risk Non-muscular Invasive Bladder Cancer","status":"NOT_YET_RECRUITING","sponsor":"SUNHO（China）BioPharmaceutical CO., Ltd.","startDate":"2024-02-15","conditions":"Bladder Cancer","enrollment":236},{"nctId":"NCT04496219","phase":"PHASE2","title":"Acupuncture for the Treatment of Intravesical BCG-Related Adverse Events in High-Risk Non-muscle Invasive Bladder Cancer","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2021-01-22","conditions":"Bladder Urothelial Carcinoma In Situ, Recurrent Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8","enrollment":45},{"nctId":"NCT00352079","phase":"PHASE3","title":"BCG With or Without Gefitinib in Treating Patients With High-Risk Bladder Cancer","status":"TERMINATED","sponsor":"NCIC Clinical Trials Group","startDate":"2007-01-04","conditions":"Bladder Cancer","enrollment":41},{"nctId":"NCT03191578","phase":"PHASE1","title":"Immunological Response to Intravesical BCG Therapy of Superficial Bladder Cancer by Prior Administration of RUTI®","status":"COMPLETED","sponsor":"Archivel Farma S.L.","startDate":"2017-06-16","conditions":"High-Risk Non-Muscle-Invasive Bladder Cancer","enrollment":44},{"nctId":"NCT00003129","phase":"PHASE2","title":"Chemotherapy in Treating Patients With Early-Stage Bladder Cancer","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"1998-09-01","conditions":"Bladder Cancer","enrollment":75},{"nctId":"NCT02948543","phase":"PHASE3","title":"Adding Mitomycin to BCG as Adjuvant Intravesical Therapy for High-risk Non-Muscle-invasive Bladder Cancer","status":"UNKNOWN","sponsor":"University of Sydney","startDate":"2013-07","conditions":"Bladder Cancer","enrollment":501},{"nctId":"NCT04943094","phase":"","title":"Clinical and Functional Consequences of Photodynamic Diagnosis (PDD) and Intravesical Instillation Therapy","status":"UNKNOWN","sponsor":"Aarhus University Hospital","startDate":"2019-09-01","conditions":"Non-muscle Invasive Bladder Cancer","enrollment":50},{"nctId":"NCT02371447","phase":"PHASE1, PHASE2","title":"VPM1002BC in Recurrent Non-muscle Invasive Bladder Cancer","status":"COMPLETED","sponsor":"Swiss Cancer Institute","startDate":"2015-09-08","conditions":"Bladder Cancer","enrollment":39},{"nctId":"NCT05701332","phase":"PHASE4","title":"Effect of Intravesical B.C.G and Gemcitabine on Semen Quality and Testicular Volume","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2023-04-01","conditions":"Urothelial Carcinoma Bladder, Sperm Count, Low, Testis; Fibrosis","enrollment":25},{"nctId":"NCT05675176","phase":"","title":"Antegrade Observational Comparative Study for the Intravesical Instillation Therapy of Bacillus Calmette Guerin With the Use of Different Types of Urinary Catheters in Patients With Urinary Bladder Cancer","status":"COMPLETED","sponsor":"National and Kapodistrian University of Athens","startDate":"2020-04-12","conditions":"Non-muscle-invasive Bladder Cancer","enrollment":100},{"nctId":"NCT00694915","phase":"PHASE2","title":"Study of Mycobacterium w in Superficial Transitional Cell Carcinoma of Bladder","status":"COMPLETED","sponsor":"Cadila Pharnmaceuticals","startDate":"2008-08-28","conditions":"Bladder Cancer","enrollment":122},{"nctId":"NCT03421236","phase":"PHASE1","title":"Intravesical Ty21a for the Treatment of Patients With Non-muscle-invasive Bladder Cancer (NMIBC)","status":"UNKNOWN","sponsor":"Patrice Jichlinski","startDate":"2018-02-18","conditions":"Non Muscle Invasive Bladder Cancer","enrollment":25},{"nctId":"NCT02365818","phase":"PHASE2","title":"Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade NMIBC After BCG Failure","status":"COMPLETED","sponsor":"CG Oncology, Inc.","startDate":"2015-06-02","conditions":"Bladder Cancer","enrollment":66},{"nctId":"NCT03664869","phase":"PHASE3","title":"Electromotive Mitomycin-C (EMDA-MMC) in Preventing Recurrences in High-risk Non-muscle-invasive Bladder Cancer","status":"UNKNOWN","sponsor":"Turku University Hospital","startDate":"2018-10-26","conditions":"Bladder Cancer","enrollment":300},{"nctId":"NCT04632537","phase":"PHASE3","title":"BCG Vaccination to Prevent COVID-19","status":"WITHDRAWN","sponsor":"Henry M. Jackson Foundation for the Advancement of Military Medicine","startDate":"2020-12-07","conditions":"COVID-19","enrollment":""},{"nctId":"NCT04723121","phase":"NA","title":"Can We Predict of the Response of High Risk Non Muscle Invasive Bladder Cancer Patients to Intravesical Bacillus Calmette-Guerin? The Role of Immunological Markers","status":"COMPLETED","sponsor":"Mansoura University","startDate":"2013-03-01","conditions":"Bladder Cancer","enrollment":204},{"nctId":"NCT04109092","phase":"PHASE1","title":"A Study of Stimulator of Interferon Genes (STING) Agonist E7766 in Non-muscle Invasive Bladder Cancer (NMIBC) Including Participants Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy, INPUT-102","status":"WITHDRAWN","sponsor":"Eisai Inc.","startDate":"2020-02-13","conditions":"Urinary Bladder Neoplasms","enrollment":""},{"nctId":"NCT03672240","phase":"PHASE1, PHASE2","title":"Study of APL-1202 in Non-Muscle Invasive Bladder Cancer Patients Who Are Resistant to One Induction Course of BCG Treatment","status":"COMPLETED","sponsor":"Asieris Pharmaceutical Technologies Co., Ltd.","startDate":"2018-11-30","conditions":"Non-Muscle Invasive Bladder Cancer (NMIBC)","enrollment":6},{"nctId":"NCT00880854","phase":"PHASE1","title":"Study of CP-675,206 in Bacillus Calmette-Guerin (BCG)-Resistant Bladder Cancer","status":"WITHDRAWN","sponsor":"University of Wisconsin, Madison","startDate":"2009-06","conditions":"Bladder Cancer","enrollment":""},{"nctId":"NCT00794950","phase":"PHASE2","title":"Bacillus Calmette-Guerin Followed by Sunitinib for the Treatment of High Risk Non-muscle Invasive Lower Urinary Tract Urothelial Carcinoma","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2009-01","conditions":"Urinary Tract Urothelial Carcinoma","enrollment":43},{"nctId":"NCT01373294","phase":"PHASE2","title":"Oral Lenalidomide and Intravesical BCG for Therapy of Bladder Cancer","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2011-11-30","conditions":"Bladder Cancer","enrollment":17},{"nctId":"NCT01878188","phase":"PHASE1","title":"Pilot Study of BC-819/PEI and BCG in Patients With Superficial Transitional Cell Bladder Carcinoma","status":"COMPLETED","sponsor":"Anchiano Therapeutics Israel Ltd.","startDate":"2013-02","conditions":"Transitional Cell Carcinoma of Bladder","enrollment":38},{"nctId":"NCT03053635","phase":"PHASE1","title":"Intravesical Photodynamic Therapy (PDT) in BCG Refractory High-Risk Non-muscle Invasive Bladder Cancer (NMIBC) Patients","status":"COMPLETED","sponsor":"Theralase® Technologies Inc.","startDate":"2016-12-21","conditions":"Non-Muscle Invasive Bladder Cancer (NMIBC) Refractory to BCG","enrollment":6},{"nctId":"NCT03038321","phase":"PHASE4","title":"Solifenacin, Levofloxacin or Lornoxicam, Which Is Ideal for Management of Intravesical Instillation BCG Side Effects?","status":"UNKNOWN","sponsor":"Mansoura University","startDate":"2017-02-01","conditions":"Non-Muscle-invasive Bladder Cancer (NMIBC), Bacillus Calmette-Guerin (BCG) Cystitis, Intra-vesical Instillation","enrollment":150},{"nctId":"NCT02326168","phase":"EARLY_PHASE1","title":"PRIME: Pilot Study Evaluating Percutaneous Vaccination of BCG for Bladder Cancer","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2013-10","conditions":"Bladder Cancer","enrollment":25},{"nctId":"NCT00234039","phase":"PHASE2","title":"S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2006-11","conditions":"Bladder Cancer","enrollment":58},{"nctId":"NCT00974818","phase":"PHASE3","title":"Mitomycin C Versus Bacillus Calmette-Guerin in the Intravesical Treatment of Non-Muscle-Invasive Bladder Cancer Patients","status":"TERMINATED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2009-09","conditions":"Bladder Cancer","enrollment":50},{"nctId":"NCT01316874","phase":"PHASE2, PHASE3","title":"Intravesical AD 32 (Valrubicin) in Patients With Carcinoma in Situ (CIS) of the Bladder Who Have Failed or Have Recurrence Following Treatment With Bacillus Calmette-guerin (BCG)","status":"COMPLETED","sponsor":"Endo Pharmaceuticals","startDate":"1993-11","conditions":"Carcinoma in Situ, Bladder Cancer","enrollment":90},{"nctId":"NCT01498172","phase":"PHASE1","title":"BCG Modulation of the recMAGE-A3 + AS15 ASCI Response in the Treatment of Non Muscle Invasive Bladder Cancer (NMIBC) Patients","status":"COMPLETED","sponsor":"Patrice Jichlinski","startDate":"2012-01","conditions":"Bladder Cancer","enrollment":23},{"nctId":"NCT01284205","phase":"PHASE3","title":"First Line Comparative Study of EN3348 (MCC) vs BCG in NMIBC","status":"WITHDRAWN","sponsor":"Bioniche Life Sciences Inc.","startDate":"2010-01","conditions":"Bladder Cancer","enrollment":""},{"nctId":"NCT01240824","phase":"EARLY_PHASE1","title":"Study of BCG + Aminophylline Toxicity When Used in the Treatment of Bladder Cancer","status":"COMPLETED","sponsor":"University of Virginia","startDate":"2010-07","conditions":"Bladder Cancer","enrollment":3},{"nctId":"NCT00002990","phase":"PHASE3","title":"Surgery and BCG in Treating Patients With Bladder Cancer","status":"COMPLETED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"1997-03","conditions":"Bladder Cancer","enrollment":1288},{"nctId":"NCT00003759","phase":"PHASE2","title":"AD 32 With or Without BCG After Surgery in Treating Patients With Newly Diagnosed or Recurrent Superficial Bladder Cancer","status":"COMPLETED","sponsor":"Anthra Pharmaceuticals","startDate":"1998-11","conditions":"Bladder Cancer","enrollment":""},{"nctId":"NCT01442519","phase":"PHASE3","title":"Sequential Bacillus Calmette-Guérin (BCG) and Electromotive Mitomycin-C Versus Bacillus Calmette-Guérin (BCG) Alone for High Risk Superficial Bladder Cancer","status":"COMPLETED","sponsor":"University of Rome Tor Vergata","startDate":"1994-01","conditions":"Bladder Cancer","enrollment":212},{"nctId":"NCT00109655","phase":"PHASE1","title":"Dose-Escalation Study of CG0070 for Bladder Cancer After BCG (Bacillus Calmette-Guerin) Failure","status":"UNKNOWN","sponsor":"Cell Genesys","startDate":"2005-04","conditions":"Carcinoma, Transitional Cell, Bladder Neoplasms","enrollment":75}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2488,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Bacillus Calmette-Guerin Vaccine Intravesical","genericName":"Bacillus Calmette-Guerin Vaccine Intravesical","companyName":"Nottingham University Hospitals NHS Trust","companyId":"nottingham-university-hospitals-nhs-trust","modality":"Biologic","firstApprovalDate":"","aiSummary":"BCG vaccine stimulates the immune system to recognize and destroy bladder cancer cells when instilled directly into the bladder. Used for Non-muscle-invasive bladder cancer (NMIBC), high-grade urothelial carcinoma, Bladder cancer recurrence prevention.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}